20 August,2021 08:20 PM IST | New Delhi | PTI
India`s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above. File Pic
Indigenously developed Zydus Cadila Covid-19 vaccine ZyCoV-D has received approval for Emergency Use Authorisation from the Drug Controller General of India and it will be administered to people 12 years and above, the Department of Biotechnology said on Friday.
This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance, it said.
The government's Department of Biotechnology (DBT) also said that the "plug-and-play" technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.
"Zydus Cadila has received approval for Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D today i.e. 20/08/2021, the world's first and India's indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above," it said.
ALSO READ
Thane man dies after being bitten by stray dog and cat
Study concluded Covid vaccine didn't increase unexplained sudden death risk: Nadda to RS
HPV vaccine not included in Universal Immunization Programme, Nadda tells LS
‘Misguided, forced to take Covid vaccines’
Demand for compensation for injuries, deaths allegedly caused by Covid vaccines
The vaccine has been developed in partnership with the DBT under Mission Covid Suraksha, the department said.
"It has been implemented by the BIRAC (Biotechnology Industry Research Assistance Council) and ZyCoV-D has been supported under the Covid-19 Research Consortia through National Biopharma Mission for preclinical studies, Phase I and Phase II clinical trials and under the Mission Covid Suraksha for Phase III Clinical Trial," the DBT said.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
